HARMAR D. BRERETON, M.D.

Plain English
This paper honors Dr. C. Norman Coleman, a renowned cancer expert, for his extensive work in tackling inequalities in cancer treatment around the world. He held various prominent positions and made significant contributions to improve access to care, especially for underserved populations. His efforts are critical because they help ensure that everyone has a fair chance of receiving effective cancer treatment, regardless of their background. Who this helps: This benefits cancer patients, especially those in disadvantaged communities.

Plain English
This study looked at how long men with locally advanced prostate cancer stay free from biochemical failure (BF) after receiving long-term hormone therapy compared to short-term hormone therapy. It found that men who were free from BF for three years had a 39% better chance of overall survival and a 73% better chance of surviving specifically from prostate cancer. Understanding this time frame can help doctors monitor patient progress and improve treatment strategies. Who this helps: This helps patients with locally advanced prostate cancer and their doctors.

Plain English
This study looked at how certain tiny RNA molecules in liver tissue can help identify the severity of hepatitis C virus (HCV) recurrence in patients after liver transplantation and differentiate it from acute cellular rejection of the liver. The researchers found that four specific microRNAs were present in higher amounts in patients with slower HCV progression, which can help in predicting the rate of liver damage. This matters because it allows for more precise treatment decisions, potentially improving patient outcomes after surgery. Who this helps: This helps patients who have received liver transplants and may face HCV recurrence.

Plain English
This study examined how melatonin, a hormone commonly associated with sleep, affects insulin and glucagon secretion in human pancreatic cells called islets. Researchers found that human islet cells have receptors for melatonin, particularly in the alpha-cells that produce glucagon, leading to increased glucagon and insulin release. Specifically, melatonin increased glucagon secretion, which indirectly boosted insulin secretion, highlighting a key difference in how melatonin behaves in humans versus rodents. Who this helps: This research benefits patients with diabetes and healthcare providers by enhancing understanding of hormone interactions in managing blood sugar levels.

Plain English
This study examined how alpha-cells (which produce glucagon) and beta-cells (which produce insulin) interact in the pancreas to influence insulin release. Researchers found that while the two types of cells can form structured clusters, the alpha-cells did not affect the beta-cells' ability to secrete insulin when directly touching them; instead, glucagon from alpha-cells boosted insulin release without needing direct contact. This matters because it helps clarify how insulin and glucagon work together in the body, which is important for understanding diabetes and its treatment. Who this helps: This benefits patients with diabetes and healthcare providers seeking better treatments.

Plain English
This study looked at two treatment options for men with locally advanced prostate cancer: long-term hormone therapy for two years and short-term hormone therapy. The researchers found that long-term therapy costs about $32,564 and provides more health benefits, giving an average of 4.13 quality-adjusted life years (QALYs), compared to $33,039 and 3.68 QALYs for short-term therapy. Overall, long-term hormone therapy is not only effective but also more cost-efficient, helping patients avoid extra treatments later on. Who this helps: This helps patients with locally advanced prostate cancer and their doctors make better treatment decisions.

Plain English
This study looked at the relationship between the time it takes for prostate-specific antigen (PSA) levels to double after treatment and the risk of dying from prostate cancer among 1,514 men. They found that shorter PSA doubling times, particularly under 6, 9, and 12 months, were strongly linked to higher cancer-specific survival rates. However, the study also revealed that PSA doubling time alone isn't enough to predict outcomes independently of the treatment type the men received, suggesting other factors are involved in cancer survival. Who this helps: This research benefits doctors and patients by highlighting the complexity of predicting prostate cancer outcomes after treatment.

Plain English
The study looked at how effective a home support program was for women with phenylketonuria (PKU) during pregnancy. It found that 53% of women receiving support (the Resource Mother group) achieved healthy blood phenylalanine levels by the 10th week of pregnancy, compared to 39% in the control group. This support helped women who started their diet after getting pregnant reach healthier levels earlier in their pregnancies. Who this helps: This benefits women with PKU who are planning to become pregnant.

Plain English
This study looked at the effects of long-term hormone therapy after initial treatment for advanced prostate cancer. It involved 1,554 patients and found that those receiving two years of additional hormone therapy had better health outcomes in most areas, especially in a subgroup with aggressive cancer, where survival rates were 81% compared to 71% in those who did not receive the long-term therapy. Despite a slight increase in some side effects, the benefits of longer hormone treatment are significant for patients. Who this helps: This helps patients with advanced prostate cancer, especially those with aggressive forms of the disease.

Plain English
This study focused on finding a specific protein called TRP-1 in liver and airway muscle cells. Researchers successfully detected two versions of this protein: a 92 kDa version in unmodified cells, which they identified as a specific form of TRP-1, and another 120 kDa version in modified cells. This discovery is important because it shows a reliable way to identify TRP-1, which could help in understanding its role in health and disease. Who this helps: Patients with respiratory issues or liver diseases, as well as doctors studying these conditions.

Plain English
This study investigated how specific sites on a channel involved in calcium transport (called TRPL) in fruit flies are affected by various molecules that regulate calcium levels. Researchers found that the TRPL channel is mostly activated by calcium interacting with a protein called calmodulin, as well as by certain signaling molecules and proteins, with notable effects observed when these proteins were altered. Specifically, the TRPL channel showed a 50% reduction in activity with one of the mutations, highlighting how these binding sites influence channel function. Who this helps: This research benefits scientists studying calcium channels and their role in cellular signaling, which can inform treatments for diseases related to calcium regulation.

Plain English
This study looks at free-standing cancer centers (FSCC) and how they improve cancer care in communities. The researchers found that FSCCs provide a wide range of services and support, which leads to better patient outcomes and more options for clinical trials. These centers can benefit local hospitals and oncologists while addressing competition and conflict of interest issues within the healthcare system. Who this helps: This helps cancer patients by providing them with more accessible and comprehensive care options.

Plain English
This study looked at how hyperbaric oxygen therapy helps patients suffering from bladder inflammation caused by radiation treatment, known as radiation-induced cystitis. In three patients who had bleeding in their urine and did not respond to usual treatments, hyperbaric oxygen therapy completely stopped the bleeding and led to noticeable healing of the bladder. This is important because it shows that hyperbaric oxygen can effectively heal damage to the bladder caused by radiation, which has not been documented before. Who this helps: This helps patients dealing with complications from cancer treatment.